Pharmacokinetics and pharmacodynamics of meldonium in exercised thoroughbred horses

Heather K Knych, Scott D Stanley, Dan S. Mckemie, Rick Arthur, Ulf Bondesson, Mikael Hedeland, Mario Thevis, Philip H Kass

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Although developed as a therapeutic medication, meldonium has found widespread use in human sports and was recently added to the World Anti-Doping Agency's list of prohibited substances. Its reported abuse potential in human sports has led to concern by regulatory authorities about the possible misuse of meldonium in equine athletics. The potential abuse in equine athletes along with the limited data available regarding the pharmacokinetics and pharmacodynamics of meldonium in horses necessitates further study. Eight exercised adult thoroughbred horses received a single oral dose of 3.5, 7.1, 14.3 or 21.4 mg/kg of meldonium. Blood and urine samples were collected and analyzed using liquid chromatography tandem mass spectrometry. Pharmacokinetic parameters were determined using non-compartmental analysis. Maximum serum concentrations ranged from 440.2 to 1147 ng/mL and the elimination half-life from 422 to 647.8 h. Serum concentrations were below the limit of quantitation by days 4, 7, 12 and 12 for doses of 3.5, 7.1, 14.3 and 21.4 mg/kg, respectively. Urine concentrations were below the limit of detection by day 44 following administration of 3.5 mg/kg and day 51 for all other dose groups. No adverse effects were observed following meldonium administration. While the group numbers were small, changes in heart rate were observed in the 3.5 mg/kg dose group (n = 1). Glucose concentrations changed significantly in all dose groups studied (n = 2 per dose group). Similar to that reported for humans, the detection time of meldonium in biological samples collected from horses is prolonged, which should allow for satisfactory regulation in performance horses.

Original languageEnglish (US)
JournalDrug Testing and Analysis
DOIs
StateAccepted/In press - 2017

Fingerprint

Pharmacodynamics
Pharmacokinetics
horse
Horses
Sports
sport
urine
serum
Urine
Liquid chromatography
Tandem Mass Spectrometry
Serum
Liquid Chromatography
Athletes
half life
Mass spectrometry
Half-Life
Limit of Detection
3-(2,2,2-trimethylhydrazine)propionate
dose

Keywords

  • Doping
  • Horse
  • Horse racing
  • LC-MS
  • Meldonium
  • Pharmacodynamics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Analytical Chemistry
  • Environmental Chemistry
  • Pharmaceutical Science
  • Spectroscopy

Cite this

Pharmacokinetics and pharmacodynamics of meldonium in exercised thoroughbred horses. / Knych, Heather K; Stanley, Scott D; Mckemie, Dan S.; Arthur, Rick; Bondesson, Ulf; Hedeland, Mikael; Thevis, Mario; Kass, Philip H.

In: Drug Testing and Analysis, 2017.

Research output: Contribution to journalArticle

@article{fc78ac3ed12b4be1a3136698b617abc4,
title = "Pharmacokinetics and pharmacodynamics of meldonium in exercised thoroughbred horses",
abstract = "Although developed as a therapeutic medication, meldonium has found widespread use in human sports and was recently added to the World Anti-Doping Agency's list of prohibited substances. Its reported abuse potential in human sports has led to concern by regulatory authorities about the possible misuse of meldonium in equine athletics. The potential abuse in equine athletes along with the limited data available regarding the pharmacokinetics and pharmacodynamics of meldonium in horses necessitates further study. Eight exercised adult thoroughbred horses received a single oral dose of 3.5, 7.1, 14.3 or 21.4 mg/kg of meldonium. Blood and urine samples were collected and analyzed using liquid chromatography tandem mass spectrometry. Pharmacokinetic parameters were determined using non-compartmental analysis. Maximum serum concentrations ranged from 440.2 to 1147 ng/mL and the elimination half-life from 422 to 647.8 h. Serum concentrations were below the limit of quantitation by days 4, 7, 12 and 12 for doses of 3.5, 7.1, 14.3 and 21.4 mg/kg, respectively. Urine concentrations were below the limit of detection by day 44 following administration of 3.5 mg/kg and day 51 for all other dose groups. No adverse effects were observed following meldonium administration. While the group numbers were small, changes in heart rate were observed in the 3.5 mg/kg dose group (n = 1). Glucose concentrations changed significantly in all dose groups studied (n = 2 per dose group). Similar to that reported for humans, the detection time of meldonium in biological samples collected from horses is prolonged, which should allow for satisfactory regulation in performance horses.",
keywords = "Doping, Horse, Horse racing, LC-MS, Meldonium, Pharmacodynamics, Pharmacokinetics",
author = "Knych, {Heather K} and Stanley, {Scott D} and Mckemie, {Dan S.} and Rick Arthur and Ulf Bondesson and Mikael Hedeland and Mario Thevis and Kass, {Philip H}",
year = "2017",
doi = "10.1002/dta.2214",
language = "English (US)",
journal = "Drug Testing and Analysis",
issn = "1942-7603",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of meldonium in exercised thoroughbred horses

AU - Knych, Heather K

AU - Stanley, Scott D

AU - Mckemie, Dan S.

AU - Arthur, Rick

AU - Bondesson, Ulf

AU - Hedeland, Mikael

AU - Thevis, Mario

AU - Kass, Philip H

PY - 2017

Y1 - 2017

N2 - Although developed as a therapeutic medication, meldonium has found widespread use in human sports and was recently added to the World Anti-Doping Agency's list of prohibited substances. Its reported abuse potential in human sports has led to concern by regulatory authorities about the possible misuse of meldonium in equine athletics. The potential abuse in equine athletes along with the limited data available regarding the pharmacokinetics and pharmacodynamics of meldonium in horses necessitates further study. Eight exercised adult thoroughbred horses received a single oral dose of 3.5, 7.1, 14.3 or 21.4 mg/kg of meldonium. Blood and urine samples were collected and analyzed using liquid chromatography tandem mass spectrometry. Pharmacokinetic parameters were determined using non-compartmental analysis. Maximum serum concentrations ranged from 440.2 to 1147 ng/mL and the elimination half-life from 422 to 647.8 h. Serum concentrations were below the limit of quantitation by days 4, 7, 12 and 12 for doses of 3.5, 7.1, 14.3 and 21.4 mg/kg, respectively. Urine concentrations were below the limit of detection by day 44 following administration of 3.5 mg/kg and day 51 for all other dose groups. No adverse effects were observed following meldonium administration. While the group numbers were small, changes in heart rate were observed in the 3.5 mg/kg dose group (n = 1). Glucose concentrations changed significantly in all dose groups studied (n = 2 per dose group). Similar to that reported for humans, the detection time of meldonium in biological samples collected from horses is prolonged, which should allow for satisfactory regulation in performance horses.

AB - Although developed as a therapeutic medication, meldonium has found widespread use in human sports and was recently added to the World Anti-Doping Agency's list of prohibited substances. Its reported abuse potential in human sports has led to concern by regulatory authorities about the possible misuse of meldonium in equine athletics. The potential abuse in equine athletes along with the limited data available regarding the pharmacokinetics and pharmacodynamics of meldonium in horses necessitates further study. Eight exercised adult thoroughbred horses received a single oral dose of 3.5, 7.1, 14.3 or 21.4 mg/kg of meldonium. Blood and urine samples were collected and analyzed using liquid chromatography tandem mass spectrometry. Pharmacokinetic parameters were determined using non-compartmental analysis. Maximum serum concentrations ranged from 440.2 to 1147 ng/mL and the elimination half-life from 422 to 647.8 h. Serum concentrations were below the limit of quantitation by days 4, 7, 12 and 12 for doses of 3.5, 7.1, 14.3 and 21.4 mg/kg, respectively. Urine concentrations were below the limit of detection by day 44 following administration of 3.5 mg/kg and day 51 for all other dose groups. No adverse effects were observed following meldonium administration. While the group numbers were small, changes in heart rate were observed in the 3.5 mg/kg dose group (n = 1). Glucose concentrations changed significantly in all dose groups studied (n = 2 per dose group). Similar to that reported for humans, the detection time of meldonium in biological samples collected from horses is prolonged, which should allow for satisfactory regulation in performance horses.

KW - Doping

KW - Horse

KW - Horse racing

KW - LC-MS

KW - Meldonium

KW - Pharmacodynamics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85026546053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026546053&partnerID=8YFLogxK

U2 - 10.1002/dta.2214

DO - 10.1002/dta.2214

M3 - Article

JO - Drug Testing and Analysis

JF - Drug Testing and Analysis

SN - 1942-7603

ER -